Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics
US9981952B2 · kind B2 · utility
0Cited by
4References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 26, 2016 |
| Grant date | May 29, 2018 |
| Priority date | — |
| Expiry date | Apr 26, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds that are agonists of the MCIR receptor and that exhibit reduced toxicity relative to other compounds of the same class are described. These compounds can have the general formula (I) wherein: R1 represents a cyclopropylmethyl or a 4-hydroxybutyl group; R2 represents a hydrogen atom or a methyl group; and also the salts and enantiomers of the corresponding compounds of general formula (I). Also described, are methods for treating hypopigmentary pathologies and photosensitive dermatoses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.